C9076 — Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
C9076 is a HCPCS Level II code for lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. It belongs to the Outpatient Prospective Payment System section. It was terminated on September 30, 2021 and is not valid on new claims.
This code has been terminated
CMS terminated C9076 on September 30, 2021. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9076
- Long descriptor
- Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Short descriptor
- Lisocabtagene car pos t
- Added
- July 1, 2021
- Terminated
- September 30, 2021
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9076
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9076 is not quite right, the correct code is very often within a few positions of it.
- C9068Copper cu-64, dotatate, diagnostic, 1 millicurieterminated
- C9069Injection, belantamab mafodontin-blmf, 0.5 mgterminated
- C9070Injection, tafasitamab-cxix, 2 mgterminated
- C9071Injection, viltolarsen, 10 mgterminated
- C9072Injection, immune globulin (asceniv), 500 mgterminated
- C9073Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9074Injection, lumasiran, 0.5 mgterminated
- C9075Injection, casimersen, 10 mgterminated
- C9077Injection, cabotegravir and rilpivirine, 2mg/3mgterminated
- C9078Injection, trilaciclib, 1 mgterminated
- C9079Injection, evinacumab-dgnb, 5 mgterminated
- C9080Injection, melphalan flufenamide hydrochloride, 1 mgterminated
- C9081Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9082Injection, dostarlimab-gxly, 100 mgterminated
- C9083Injection, amivantamab-vmjw, 10 mgterminated
- C9084Injection, loncastuximab tesirine-lpyl, 0.1 mgterminated
Questions about C9076
What is HCPCS code C9076?
C9076 is a HCPCS Level II code for lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9076?
The CMS HCPCS file marks C9076 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9076 still valid?
No. C9076 was terminated on September 30, 2021 and should not be used on new claims.